Business model and strategy

Created in 1997, BioAlliance Pharma develops its activities and focuses them on rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections – to respond to the needs of specialist physicians, particularly in the hospital setting.

The Company designs and manufactures innovative products, based on active pharmaceutical ingredients already recognized on the market with a proven efficacy and tolerance profile, as well as developing new entities. It more specifically targets diseases for which the medical needs are insufficiently met and where the phenomenon of drug resistance leads to particularly serious consequences.

Our teams have the key competencies required to identify, design, develop and register drugs in Europe and the USA. Our development choices enable us to balance the risks in our product portfolio and to accelerate market launch of our products.

Positioning itself on our targeted markets, with strategic experienced partners in Europe (Therabel), USA (Par Pharmaceutical/Strativa) and Asia (Handok and NovaMed) BioAlliance Pharma has consistent and experienced structures to organize the commercialization of its first two products, Loramyc® and Setofilm®, and to generate a recurring revenue stream.

.